{"id":54844,"date":"2023-03-15T08:03:14","date_gmt":"2023-03-15T07:03:14","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/transgene-to-present-multiple-posters-highlighting-the-potential-of-its-exciting-immunotherapy-pipeline-at-aacr-2023\/"},"modified":"2023-03-15T08:03:14","modified_gmt":"2023-03-15T07:03:14","slug":"transgene-to-present-multiple-posters-highlighting-the-potential-of-its-exciting-immunotherapy-pipeline-at-aacr-2023","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/transgene-to-present-multiple-posters-highlighting-the-potential-of-its-exciting-immunotherapy-pipeline-at-aacr-2023\/","title":{"rendered":"Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023"},"content":{"rendered":"<div>\n<p>\nNew Phase I data confirm high immunogenicity and promising efficacy profile of TG4050, an individualized neoantigen cancer vaccine developed by Transgene in collaboration with NEC Corporation\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230314005844\/en\/1192643\/5\/Logo_Transgene.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230314005844\/en\/1192643\/21\/Logo_Transgene.jpg\"><\/a><\/p>\n<p>\nExciting preclinical data on the novel IV oncolytic virus candidate TG6050\n<\/p>\n<p>STRASBOURG, France&#8211;(BUSINESS WIRE)&#8211;<a href=\"https:\/\/twitter.com\/hashtag\/HBV?src=hash\" target=\"_blank\" rel=\"noopener\">#HBV<\/a>&#8211;Regulatory News:\n<\/p>\n<p>\n<b>Transgene (Euronext Paris: TNG) (Paris:TNG),<\/b><b> <\/b>a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, <b>will be presenting eight posters on its clinical and preclinical immunotherapies at the AACR<\/b> (American Association for Cancer Research) Annual Meeting 2023, which will take place in Orlando, Florida, USA, April 14 \u2013 19.\n<\/p>\n<p>\n<b>The posters highlight:<\/b>\n<\/p>\n<p class=\"bwmarginl1\">\n\u2713 <b>the potential of Transgene\u2019s novel cancer vaccines and oncolytic viruses to change the solid tumor treatment landscape in challenging clinical settings, and<br \/>\n<br \/><\/b>\u2713 <b>the advances that Transgene has made with its two technology platforms.<\/b>\n<\/p>\n<p>\nThe details on the upcoming poster presentations are:\n<\/p>\n<p>\n<b>TG4050<br \/>\n<br \/><\/b><b>Title: <i>Feasibility and immunogenicity of adjuvant TG4050, a patient tailored cancer vaccine in head and neck and ovarian cancer<\/i><\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<span class=\"bwuline\">Session title<\/span>: Late-Breaking Research: Clinical Research 2\n<\/li>\n<li>\n<span class=\"bwuline\">Poster and abstract number<\/span>: LB205\n<\/li>\n<li>\n<span class=\"bwuline\">Date and Time: <\/span>Tuesday April 18, 2023; 9:00 a.m. &#8211; 12:30 p.m. ET\n<\/li>\n<li>\n<span class=\"bwuline\">Location:<\/span> Board 20, Section 35\n<\/li>\n<li>\n<span class=\"bwuline\">Authors<\/span>: Ana Lalanne, Camille Jamet, Christian H. Ottensmeier, Jean-Pierre Delord, Christophe Le Tourneau, Matthew S. Block, Gerardo Colon-Otero, Keith L. Knutson, Annette Tavernaro, Gisele Lacoste, Benoit Grellier, Xavier Noiriel, Thierry Huss, Bernard Burtin, Yoshiko Yamashita, Kousuke Onoue, Kazuhide Onoguchi, Brandon Malone, Olivier Lantz, Oliver Baker, Naoko Yamagata, Yuki Tanaka, Eric Quemeneur, Maud Brandely, Ka\u00efdre Bendjama\n<\/li>\n<\/ul>\n<p>\n<b>TG4001<br \/>\n<br \/><\/b><b>Title: <i>A randomized phase II trial of TG4001 plus avelumab versus avelumab alone in recurrent\/metastatic (R\/M) human papilloma virus (HPV)-16 positive anogenital cancers<\/i><\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<span class=\"bwuline\">Session title<\/span>: Phase II and Phase III Clinical Trials in Progress\n<\/li>\n<li>\n<span class=\"bwuline\">Poster and abstract number<\/span>: CT045\n<\/li>\n<li>\n<span class=\"bwuline\">Date and Time: <\/span>Monday April 17, 2023; 9:00 a.m. &#8211; 12:30 p.m. ET\n<\/li>\n<li>\n<span class=\"bwuline\">Location:<\/span> Board 3, Section 46\n<\/li>\n<li>\n<span class=\"bwuline\">Authors<\/span>: Christophe Le Tourneau, Fr\u00e9d\u00e9ric Rolland, Amaury Daste, Philippe Cassier, S\u00e9bastien Salas, Luis Manso S\u00e1nchez, Gerardo Colon-Otero, Lauriane Eberst, Olivier Lantz, Ana Lalanne, Annette Tavernaro, Hakim Makhloufi, Ka\u00efdre Bendjama, Maud Brandely, Jean-Pierre Delord.\n<\/li>\n<\/ul>\n<p>\n<b>TG6002<br \/>\n<br \/><\/b><b>Title: <i>Oncolytic virus TG6002 safety and activity after intrahepatic artery administration in patients with liver-dominant metastatic colorectal cancer<\/i><\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<span class=\"bwuline\">Session title<\/span>: Phase I Clinical Trials 1\n<\/li>\n<li>\n<span class=\"bwuline\">Poster and abstract number<\/span>: CT190\n<\/li>\n<li>\n<span class=\"bwuline\">Date and Time: <\/span>Tuesday April 18, 2023; 9:00 a.m. &#8211; 12:30 p.m. ET\n<\/li>\n<li>\n<span class=\"bwuline\">Location:<\/span> Board 3, Section 46\n<\/li>\n<li>\n<span class=\"bwuline\">Authors<\/span>: Adel Samson, Cristina Smolenschi, Philippe Cassier, Jai V. Patel, Chris Hammond, Marta Kurzawa, Sophie Sainte-Croix, Emma West, Alain Sadoun, Kaidre Bendjama\n<\/li>\n<\/ul>\n<p>\n<b>TG6050<br \/>\n<br \/><\/b><b>Title: <i>TG6050 an oncolytic vaccinia virus armed with interleukin 12 and anti-CTLA4 antibody induces TME remodeling and strong anti-tumoral responses<\/i><\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<span class=\"bwuline\">Session title<\/span>: Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies\n<\/li>\n<li>\n<span class=\"bwuline\">Poster and abstract number<\/span>: 694\n<\/li>\n<li>\n<span class=\"bwuline\">Date and Time:<\/span> Sunday Apr 16, 2023; 1:30 p.m. &#8211; 5:00 p.m. ET\n<\/li>\n<li>\n<span class=\"bwuline\">Location:<\/span> Board 14, Section 24\n<\/li>\n<li>\n<span class=\"bwuline\">Authors<\/span>: Jean-Baptiste Marchand, Fadi Azar, Christelle Demeusoit, Patricia Kleinpeter, Jules Deforges, Laetitia Fend, Chantal Hoffmann, Huguette Schultz, Nathalie Silvestre, Eric Qu\u00e9m\u00e9neur\n<\/li>\n<\/ul>\n<p>\n<b>R&amp;D<\/b>\n<\/p>\n<p>\n<b>Title: <i>Selection of an optimal anti-PD-L1 single domain antibody format for the vectorization into oncolytic vaccinia virus and the generation of bispecific immunomodulators.<\/i><\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<span class=\"bwuline\">Session title<\/span>: Therapeutic Antibodies 1\n<\/li>\n<li>\n<span class=\"bwuline\">Poster and abstract number<\/span>: 1885\n<\/li>\n<li>\n<span class=\"bwuline\">Date and Time: <\/span>Monday April 17, 2023; 9:00 a.m. &#8211; 12:30 p.m. ET\n<\/li>\n<li>\n<span class=\"bwuline\">Location:<\/span> Board 24, Section 25\n<\/li>\n<li>\n<span class=\"bwuline\">First author<\/span>: Jean-Baptiste Marchand\n<\/li>\n<\/ul>\n<p>\n<b>Title: <i>Advanced patient-derived lung tumoroids to identify limiting factors for oncolytic virotherapy<\/i><\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<span class=\"bwuline\">Session title<\/span>: Tumor-Stromal Cell (Including Immune Cell) Interactions and Therapy Responses\n<\/li>\n<li>\n<span class=\"bwuline\">Poster and abstract number<\/span>: 5967\n<\/li>\n<li>\n<span class=\"bwuline\">Date and Time: <\/span>Wednesday April 19, 2023; 9:00 a.m. &#8211; 12:30 p.m. ET\n<\/li>\n<li>\n<span class=\"bwuline\">Location:<\/span> Board 28, Section 7\n<\/li>\n<li>\n<span class=\"bwuline\">First author<\/span>: Helene Le\n<\/li>\n<\/ul>\n<p>\n<b>Title: <i>Extracellular vesicles (EV): mediators of therapeutic vaccination? In vivo and in vitro characterization of EVs generated after infection of human and murine cells with therapeutic poxviruses<\/i><\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<span class=\"bwuline\">Session title<\/span>: Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies<span class=\"bwuline\">Poster and abstract number<\/span>: 697\n<\/li>\n<li>\n<span class=\"bwuline\">Date and Time <\/span>Sunday Apr 16, 2023; 1:30 p.m. &#8211; 5:00 p.m. ET\n<\/li>\n<li>\n<span class=\"bwuline\">Location:<\/span> Board 17, Section 24\n<\/li>\n<li>\n<span class=\"bwuline\">First author<\/span>: Lucas Walther\n<\/li>\n<\/ul>\n<p>\n<b>Title: PoxSTG, a novel chimeric poxvirus with improved oncolytic potency<\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<span class=\"bwuline\">Session title<\/span>: Vaccines\n<\/li>\n<li>\n<span class=\"bwuline\">Poster and abstract number<\/span>: 6796\n<\/li>\n<li>\n<span class=\"bwuline\">Date and Time:<\/span> Wednesday Apr 19, 2023; 9:00 a.m. &#8211; 12:30 p.m. ET\n<\/li>\n<li>\n<span class=\"bwuline\">Location: Board 12, Section 44<\/span>\n<\/li>\n<li>\n<span class=\"bwuline\">First author<\/span>: Philippe Erbs\n<\/li>\n<\/ul>\n<p>\nIn addition to presenting these posters, Transgene will also be hosting a booth during the AACR congress.\n<\/p>\n<p class=\"bwalignc\">\n***\n<\/p>\n<p>\n<b><i>About Transgene<br \/>\n<br \/><\/i><\/b>Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene\u2019s programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.<br \/>\n<br \/>The Company\u2019s clinical-stage programs consist of a portfolio of therapeutic vaccines and oncolytic viruses:<br \/>\n<br \/>TG4050, the first individualized therapeutic vaccine based on the <i>myvac<\/i>\u00ae platform, TG4001 for the treatment of HPV-positive cancers, as well as TG6002, BT-001 and TG6050, three oncolytic viruses based on the Invir.IO\u00ae viral backbone.<br \/>\n<br \/>With Transgene\u2019s <i>myvac<\/i>\u00ae platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The <i>myvac<\/i>\u00ae approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.<br \/>\n<br \/>With its proprietary platform Invir.IO\u00ae, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses. Transgene has an ongoing Invir.IO\u00ae collaboration with AstraZeneca.<br \/>\n<br \/>Additional information about Transgene is available at: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.transgene.fr%2F&amp;esheet=53361901&amp;newsitemid=20230314005844&amp;lan=en-US&amp;anchor=www.transgene.fr&amp;index=1&amp;md5=bb6c5bbf150fc33300fe85a422e8de26\" rel=\"nofollow noopener\" shape=\"rect\">www.transgene.fr<\/a><br \/>Follow us on social media: Twitter: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Ftransgenesa&amp;esheet=53361901&amp;newsitemid=20230314005844&amp;lan=en-US&amp;anchor=%40TransgeneSA&amp;index=2&amp;md5=a87054de0f36dcd6f187f29c143ffa9c\" rel=\"nofollow noopener\" shape=\"rect\">@TransgeneSA<\/a><span class=\"bwuline\"> <\/span>\u2013 LinkedIn:<span class=\"bwuline\"> <\/span><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Ftransgene&amp;esheet=53361901&amp;newsitemid=20230314005844&amp;lan=en-US&amp;anchor=%40Transgene&amp;index=3&amp;md5=2511d1335d27c12b1b1a6e539c018ce0\" rel=\"nofollow noopener\" shape=\"rect\">@Transgene<\/a>\n<\/p>\n<p>\n<b><i>About NEC Corporation<br \/>\n<br \/><\/i><\/b>NEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of \u201cOrchestrating a brighter world\u201d. NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.nec.com&amp;esheet=53361901&amp;newsitemid=20230314005844&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.nec.com&amp;index=4&amp;md5=c4afab8ef74840e04a7099e76cf36c92\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.nec.com<\/a> and NEC\u2019s AI Drug Development Business at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.nec.com%2Fen%2Fglobal%2Fsolutions%2Fai-drug%2F&amp;esheet=53361901&amp;newsitemid=20230314005844&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.nec.com%2Fen%2Fglobal%2Fsolutions%2Fai-drug%2F&amp;index=5&amp;md5=53c1aa0f39215dacd4ca6dd10aeb1368\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.nec.com\/en\/global\/solutions\/ai-drug\/<\/a>\n<\/p>\n<p>\n<b><i>Disclaimer<br \/>\n<br \/><\/i><\/b><i>This press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company\u2019s activities, perspectives, financial situation, results, regulatory authorities\u2019 agreement with development phases, and development. The Company\u2019s ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and\/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company\u2019s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (\u201cFacteurs de Risque\u201d) section of the Universal Registration Document, available on the AMF website (<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.amf-france.org&amp;esheet=53361901&amp;newsitemid=20230314005844&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.amf-france.org&amp;index=6&amp;md5=79ada6722d8d78374dba75e5b92a6b22\" rel=\"nofollow noopener\" shape=\"rect\">http:\/\/www.amf-france.org<\/a>) or on Transgene\u2019s website (<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.transgene.fr&amp;esheet=53361901&amp;newsitemid=20230314005844&amp;lan=en-US&amp;anchor=www.transgene.fr&amp;index=7&amp;md5=a97d95342b6705db909c562c9d828a23\" rel=\"nofollow noopener\" shape=\"rect\">www.transgene.fr<\/a>). Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.<\/i>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Transgene:<\/b><br \/><b>Lucie Larguier<\/b><br \/>Director Corporate Communications &amp; IR<br \/>\n<br \/>+33 (0)3 88 27 91 04<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;&#105;&#x6c;&#x74;&#111;&#58;&#x69;&#x6e;&#118;&#101;&#x73;&#x74;&#111;&#114;&#x72;&#x65;&#108;&#97;&#x74;&#x69;&#111;&#110;&#x73;&#x40;&#116;&#114;&#x61;&#x6e;&#115;&#103;&#x65;&#x6e;&#101;&#46;&#x66;&#x72;\" rel=\"nofollow noopener\" shape=\"rect\">i&#110;&#118;&#x65;&#x73;&#x74;or&#114;&#101;&#x6c;&#x61;&#x74;i&#111;&#110;&#115;&#x40;&#x74;&#x72;a&#110;&#115;&#x67;&#x65;&#x6e;e&#46;&#102;&#114;<\/a>\n<\/p>\n<p>\n<b>Media: MEDiSTRAVA Consulting<\/b><br \/><b>David Dible\/Sylvie Berrebi\/George Underwood<\/b><br \/>+44 (0)203 928 6900<br \/>\n<br \/><a target=\"_blank\" href=\"m&#97;&#105;&#x6c;&#x74;&#x6f;:&#116;&#114;&#x61;&#x6e;&#x73;ge&#110;&#x65;&#x40;&#x6d;ed&#105;&#115;&#x74;&#x72;&#x61;v&#97;&#46;&#x63;&#x6f;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x74;&#114;a&#x6e;&#x73;&#103;e&#x6e;&#x65;&#64;m&#x65;&#100;i&#x73;&#x74;&#114;a&#x76;&#x61;&#46;c&#x6f;&#109;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>New Phase I data confirm high immunogenicity and promising efficacy profile of TG4050, an individualized neoantigen cancer vaccine developed by Transgene in collaboration with NEC Corporation Exciting preclinical data on the novel IV oncolytic virus candidate TG6050 STRASBOURG, France&#8211;(BUSINESS WIRE)&#8211;#HBV&#8211;Regulatory News: Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/transgene-to-present-multiple-posters-highlighting-the-potential-of-its-exciting-immunotherapy-pipeline-at-aacr-2023\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54844","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/transgene-to-present-multiple-posters-highlighting-the-potential-of-its-exciting-immunotherapy-pipeline-at-aacr-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"New Phase I data confirm high immunogenicity and promising efficacy profile of TG4050, an individualized neoantigen cancer vaccine developed by Transgene in collaboration with NEC Corporation Exciting preclinical data on the novel IV oncolytic virus candidate TG6050 STRASBOURG, France&#8211;(BUSINESS WIRE)&#8211;#HBV&#8211;Regulatory News: Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/transgene-to-present-multiple-posters-highlighting-the-potential-of-its-exciting-immunotherapy-pipeline-at-aacr-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-15T07:03:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230314005844\/en\/1192643\/21\/Logo_Transgene.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-to-present-multiple-posters-highlighting-the-potential-of-its-exciting-immunotherapy-pipeline-at-aacr-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-to-present-multiple-posters-highlighting-the-potential-of-its-exciting-immunotherapy-pipeline-at-aacr-2023\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023\",\"datePublished\":\"2023-03-15T07:03:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-to-present-multiple-posters-highlighting-the-potential-of-its-exciting-immunotherapy-pipeline-at-aacr-2023\\\/\"},\"wordCount\":1214,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-to-present-multiple-posters-highlighting-the-potential-of-its-exciting-immunotherapy-pipeline-at-aacr-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230314005844\\\/en\\\/1192643\\\/21\\\/Logo_Transgene.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-to-present-multiple-posters-highlighting-the-potential-of-its-exciting-immunotherapy-pipeline-at-aacr-2023\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-to-present-multiple-posters-highlighting-the-potential-of-its-exciting-immunotherapy-pipeline-at-aacr-2023\\\/\",\"name\":\"Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-to-present-multiple-posters-highlighting-the-potential-of-its-exciting-immunotherapy-pipeline-at-aacr-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-to-present-multiple-posters-highlighting-the-potential-of-its-exciting-immunotherapy-pipeline-at-aacr-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230314005844\\\/en\\\/1192643\\\/21\\\/Logo_Transgene.jpg\",\"datePublished\":\"2023-03-15T07:03:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-to-present-multiple-posters-highlighting-the-potential-of-its-exciting-immunotherapy-pipeline-at-aacr-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-to-present-multiple-posters-highlighting-the-potential-of-its-exciting-immunotherapy-pipeline-at-aacr-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-to-present-multiple-posters-highlighting-the-potential-of-its-exciting-immunotherapy-pipeline-at-aacr-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230314005844\\\/en\\\/1192643\\\/21\\\/Logo_Transgene.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230314005844\\\/en\\\/1192643\\\/21\\\/Logo_Transgene.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-to-present-multiple-posters-highlighting-the-potential-of-its-exciting-immunotherapy-pipeline-at-aacr-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/transgene-to-present-multiple-posters-highlighting-the-potential-of-its-exciting-immunotherapy-pipeline-at-aacr-2023\/","og_locale":"en_US","og_type":"article","og_title":"Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023 - Pharma Trend","og_description":"New Phase I data confirm high immunogenicity and promising efficacy profile of TG4050, an individualized neoantigen cancer vaccine developed by Transgene in collaboration with NEC Corporation Exciting preclinical data on the novel IV oncolytic virus candidate TG6050 STRASBOURG, France&#8211;(BUSINESS WIRE)&#8211;#HBV&#8211;Regulatory News: Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/transgene-to-present-multiple-posters-highlighting-the-potential-of-its-exciting-immunotherapy-pipeline-at-aacr-2023\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-15T07:03:14+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230314005844\/en\/1192643\/21\/Logo_Transgene.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/transgene-to-present-multiple-posters-highlighting-the-potential-of-its-exciting-immunotherapy-pipeline-at-aacr-2023\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/transgene-to-present-multiple-posters-highlighting-the-potential-of-its-exciting-immunotherapy-pipeline-at-aacr-2023\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023","datePublished":"2023-03-15T07:03:14+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/transgene-to-present-multiple-posters-highlighting-the-potential-of-its-exciting-immunotherapy-pipeline-at-aacr-2023\/"},"wordCount":1214,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/transgene-to-present-multiple-posters-highlighting-the-potential-of-its-exciting-immunotherapy-pipeline-at-aacr-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230314005844\/en\/1192643\/21\/Logo_Transgene.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/transgene-to-present-multiple-posters-highlighting-the-potential-of-its-exciting-immunotherapy-pipeline-at-aacr-2023\/","url":"https:\/\/pharma-trend.com\/en\/transgene-to-present-multiple-posters-highlighting-the-potential-of-its-exciting-immunotherapy-pipeline-at-aacr-2023\/","name":"Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/transgene-to-present-multiple-posters-highlighting-the-potential-of-its-exciting-immunotherapy-pipeline-at-aacr-2023\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/transgene-to-present-multiple-posters-highlighting-the-potential-of-its-exciting-immunotherapy-pipeline-at-aacr-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230314005844\/en\/1192643\/21\/Logo_Transgene.jpg","datePublished":"2023-03-15T07:03:14+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/transgene-to-present-multiple-posters-highlighting-the-potential-of-its-exciting-immunotherapy-pipeline-at-aacr-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/transgene-to-present-multiple-posters-highlighting-the-potential-of-its-exciting-immunotherapy-pipeline-at-aacr-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/transgene-to-present-multiple-posters-highlighting-the-potential-of-its-exciting-immunotherapy-pipeline-at-aacr-2023\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230314005844\/en\/1192643\/21\/Logo_Transgene.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230314005844\/en\/1192643\/21\/Logo_Transgene.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/transgene-to-present-multiple-posters-highlighting-the-potential-of-its-exciting-immunotherapy-pipeline-at-aacr-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54844","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54844"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54844\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54844"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54844"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54844"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}